

DAFTAR PUSTAKA

- Accelrys Enterprise Platform. (2005). *Introduction to the Discovery Studio Visualizer*. Accelrys Software Inc.
- Acosta EP. (2018). Antiviral Agents (Nonretroviral), In Goodman & Gilman's: The Pharmacological Basis of Therapeutics. *McGraw-Hill Medical*, 13e, 1105–1116.
- Amelia F. (2015). *Modeling Struktur Protein Vaksin H5n1 HA BTB Menggunakan I-Tasser*.
- Baden LR and Rubin EJ. (2020). Covid-19 - The Search for Effective Therapy. *N Engl J Med*. <https://doi.org/10.1056/NEJMe2005477>
- Bajorath, J. (2015). *Computer-Aided Drug Discovery 4*. F1000Research.
- Boriskin YS and Leneva IA, Pecheur EI, P. S. (2020). Arbidol: A Broad-spectrum Antiviral Compound that Blocks Viral Fusion. *Curr Med Chem*, 15(10), 997–1005. <https://doi.org/10.2174/092986708784049658>
- Burhan E, Dwi Susanto A, A Nasution EG, Wicaksono PC, Susilo A, Firdaus AI, Santoso, Arifa JD, Kamsul AS, Wulung L, Damayanti T, dkk. (2020). Pneumonia COVID-19: Diagnosis dan Penatalaksanaan di Indonesia. *Perhimpunan Dokter Paru Indonesia*.
- Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. (2020). Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. *Engineering*. <https://doi.org/10.1016/j.eng.2020.03.007>
- Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. (2020). A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. *N Engl J Med*. <https://doi.org/10.1056/NEJMoa2001282>
- Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. (2020). Epidemiological and Clinical Characteristics of 99 Cases of 2019 Novel Coronavirus Pneumonia in Wuhan, China: A Descriptive Study. *Lancet*, 395(10223), 507–13. [https://doi.org/10.1016/S0140-6736\(20\)30211-7](https://doi.org/10.1016/S0140-6736(20)30211-7)
- COVID-19 Treatment Guidelines Panel. (2020). *COVID-19 Treatment Guidelines*. <https://www.covid19treatmentguidelines.nih.gov/>
- de Wit E, van Doremalen N, Falzarano D, M. V. (2016). SARS and MERS: Recent Insights into Emerging Coronaviruses. *Nat Rev Microbiol*, 14(8), 523–534.
- Deng L, Li C, Zeng Q, Liu X, Li X, Zhang H, et al. (2020). Arbidol Combined with LPV/r Versus LPV/r Alone Against Corona Virus Disease 2019: A Retrospective Cohort Study. *J Infect*, S0163-4453(40), 30113. <https://doi.org/10.1016/j.jinf.2020.03.002>
- Devaux CA, Rolain JM, Colson P, R. D. (2020). New Insights on the Antiviral Effects of Chloroquine against Coronavirus: What to Expect for COVID-19. *Int J Antimicrob Agents*, 55(5), 105938. <https://doi.org/10.1016/j.ijantimicag.2020.1059368>

- Dong L, Hu S, G. J. (2020). Discovering Drugs to Treat Coronavirus Disease 2019 (COVID-19). *Drug Discov Ther*, 14(1), 58–60.
- Du, X., dan Qu, C. (2020). Guidance for Corona Virus Disease 2019: Prevention, Control, Diagnosis and Management. *People's Medical Publishing Hpuse*.
- Fatchiyyah. (2015). *Prinsip Dasar Bioinformatika*. Universitas Brawijaya Press.
- Ferreira LG, Santos RN, Oliva G, A. A. (2015). Molecular Docking and Structure-Based Drug Design Strategies. *Molecules*, 20, 13384–13400.
- Frimayanti, N. (2021). Simulasi Molecular Dynamic (MD) Senyawa Analog Kalkon Sebagai Inhibitor Untuk Sel Kanker Paru A549. *Jurnal Penelitian Farmasi Indonesia*, 9(2), 56–60. <https://doi.org/10.51887/jpfi.v9i2.852>
- Furuta Y, Komeno T, N. T. (2017). Favipiravir (T-705), a Broad Spectrum Inhibitor of Viral RNA Polymerase. *Proc Jpn Acad Ser B Phys Biol Sci*, 93(7), 449–63. <https://doi.org/10.2183/pjab.93.027>
- Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. (2020). Hydroxychlorouine and Azithromycin as a Treatment of COVID-19: Results of an Open-label Non-randomized Clinical Trial. *Int J Antimicrob Agents*, 105949. <https://doi.org/10.1016/j.ijantimicag.2020.105949>
- Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA, et al. (2020). The Species Severe Acute Respiratory Syndrome-related Coronavirus: Classifying 2019-nCoV and Naming it SARS-CoV-2. *Nat Microbiol*. <https://doi.org/10.1038/s41564-020-0695-z>
- Graci JD and Cameron CE. (2006). Mechanisms of Action of Ribavirin against Distinct Viruses. *Rev Med Virol*, 16(1), 37–48. <https://doi.org/10.1002/rmv.483>
- Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. (2020). Compassionate Use of Remdesivir for Patients with Severe COVID-19. *M Engl J Med*.
- Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. (2020). Clinical Characteristics of Coronavirus Disease 2019 in China. *New Engl J Med*. <https://doi.org/10.1056/NEJMoa2002032>
- Hu B, Zeng LP, Yang XL, Ge XY, Zhang W, Li, B, Xie JZ, Shen XR, Zhang YZ, Wang N, et al. (2017). Discovery of a Rich Gene Pool of bat SARS-Related Coronaviruses Provides New Insights Into the Origin of SARS Coronavirus. *PLoS Pathog*, 13e1006698.
- Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. (2020). Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan, China. *Lancet*, 395(10223), 497–506.
- I Siswandono. (2016). *Kimia Medisinal 1* (Siswandono (ed.); 2nd ed.). Airlangga University Press.
- Junaidin, Chaerani S, dan F. N. (2019). Studi Homologi Modeling Enzim Tironase (Homo Sapiens) dengan Menggunakan Swiss-Model. *Jurnal Farmagazine*.

- Kementerian Kesehatan Republik Indonesia. (2020). *Situasi Terkini Perkembangan Novel Coronavirus (COVID-19)*. August 31, 2020. <https://covid19.kemkes.go.id/situasi-infeksi-emerging/infocoronavirus/situasi-terkiniperkembangan-coronavirusdisease-covid-19-31-agustus-2020/#.X0y2bNwzZxQ>
- Kementerian Kesehatan Republik Indonesia. (2021). *Direktorat Jenderal Pencegahan dan Pengendalian Penyakit: Pedoman Pencegahan dan Pengendalian Coronavirus Disease (COVID-19)*.
- Kim UJ, Won EJ, Kee SJ, Jung SI, J. H. (2016). Combination Therapy with Lopinavir/Ritonavir, Ribavirin and Interferon- α for Middle East Respiratory Syndrome. *Antivir Ther*, 21(5), 455–9. <https://doi.org/10.3851IMP3002>
- Kopidpedia. (2020). *Bunga Rampai Artikel Penyakit Virus Korona (COVID-19)*. Fakultas Kedokteran Universitas Islam Bandung.
- Lelita R, Gunawan R, dan A. W. (2017). Studi Docking Molekular Senyawa Kuersetin, Kalkon dan Turunanya sebagai Inhibitor Sel Kanker Payudara MC-7 (Michigan Cancer Foundation-7). *Jurnal Atomik*, 1(2), 190–196.
- Li, R., Qiao, S., Zhang, G. (2020). Analysis of angiotensin-converting enzyme 2 (ACE2) from different species sheds some light on cross-species receptor usage of a novel coronavirus 2019-nCoV. *J. Infect*, 80(4), 469–496.
- Lim J, Jeon S, Shin HY, Kim MJ, Seong YM, Lee WJ, et al. (2020). Case of the Index Patient Who Caused Tertiary Transmission of COVID-19 Infection in Korea: The Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Infected Pneumonia Monitored by Quantitative RTPCR. *J Korean Med Sci*, 35(6e), 79. <https://doi.org/10.3346/jkms.2020.35.e79>
- Liu DX., Fung TS, Chong KKL, Shukla A, H. R. (2014). Accessory Proteins of SARS-CoV and Other Coronaviruses. *Antivir Res*, 109, 97–109.
- Liu Y, Gayle AA, Wilder-Smith A, R. J. (2020). The Reproductive Number of COVID-19 is Higher Compared to SARS Coronavirus. *J Travel Med*, 27(2).
- M Yu. (2012). *Computational Modelling of Protein Dynamic*. San Joe State University.
- MMV. (2011). *Molegro Molecular Viewer User Manual*.
- Morse JS. (2020). Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV. *ChemBioChem*. <https://doi.org/10.1002/cbic.202000047>
- Motiejunas D and Wade R. (2006). Structural, Energetics, and Dynamic Aspects of Ligand-Receptor Interactions. *Comprehensive Medicinal Chemistry II. Computer-Assisted Drug Design*, 4(4), 193–214.
- Mourad JJ and Levy BI. (2020). Interaction between RAAS inhibitors and ACE2 in the context of COVID-19. *Nat Rev Cardiol*, 17, 313. <https://doi.org/Nat Rev Cardiol>
- Muttaqin FZ, Pratama MF, dan K. F. (2019). Molecular Docking and Molecular Dynamic Studies of Stilbene Derivative Compounds as Sirtuin-3 (SIRT3) Histone Deacetylase Inhibitor on Melanoma Skin Cancer and Their

- Toxicities Prediction. *Journal of Pharmacopolium*, 2(2), 112–121.
- Pacheco, A. B., & Hpc, L. S. U. (2012). *Introduction to AutoDock and AutoDock Tools*.
- Pangastuti A, Amin M, dan I. S. (2016). Mengungkapkan Potensi Senyawa Alami melalui Teknik Reverse Docking. *Prosiding Seminal Nasional II*, 668–674.
- Purwaniati dan Asnawi, A. (2020). Target Kerja Obat Antivirus COVID-19: Review. *Jurnal Farmagazine*, VII(2), 30–42.
- Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, Tian DS, et al. (2020). Dysregulation of Immune Response in Patients with COVID-19 in Wuhan, China. *Clinical Infectious Diseases*.
- Rachmania, R. (2019). Antiproliferasi Sel Kanker Berbasis Bahan Alam terhadap Reseptor Cyclin-Dependent Kinase 4 (Cdk 4). *Jurnal Ilmu Farmasi*, 16(1), J. Ilmu Farm. <https://doi.org/10.12928/mf.v16i1.12101>
- Riedel S, Morse S, Mietzner T, Miller S, Jawetz, Melnick, and A. (2019). *Medical Microbiology 28th ed. McGrawHill Medical*, 617–622.
- Rock BM, Hengel SM, Rock DA, Wienkers LC, K. K. (2014). Characterization of Ritonavir-mediated Inactivation of Cytochrome P450 3A4. *Mol Pharmacol*, 86(6), 665–74. <https://doi.org/10.1124/mol.114.094862>
- RSCB. (2014). *About the PDB Archive and the RCSB PDB*. Protein Data Bank. http://www.rcsb.org/pdb/static.do?p=general_information/about_pdb/index.html
- Ruswanto, Tita Nofianti, Richa Mardianingrum, Tresna Lestari, A. S. (2018). Desain dan Studi In Silico Senyawa Turunan Kuwanon-H sebagai Kandidat Obat Anti-HIV. *Jurnal Kimia VALENSI: Jurnal Penelitian Dan Pengembangan Ilmu Kimia*, 4(1), 57–66.
- Ruswanto R, Rahayuningsih N, Hidayati NL, Nuryani GS, M. R. (2019). Uji In Vitro dan Studi In Silico Senyawa Turunan N⁷-Benzoylisonicotinohydrazide sebagai Kandidat Antituberkolosis. *Jurnal Ilmu Kefarmasian Indonesia*, 2614–6495.
- Ruswanto, R. (2015). Molecular Docking Empat Turunan Isonicotinohydrazide pada Mycobacterium Tuberculosis Enoyl-Acyl Carrier Protein Reductase (InhA). *Jurnal Kesehatan Bakti Tunas Husada: Jurnal Ilmu-Ilmu Keperawatan, Analisis Kesehatan Dan Farmasi*, 13(1), 135–141. <https://doi.org/10.36465/jkbth.v13i1.25>
- Ruswanto, Siswandono, Richa, M., Tita, N., & Tresna, L. (2017). Molecular Docking of 1-Benzoyl-3-Methylthiourea as Anti Cancer Candidate and Its Absorption, Distribution, and Toxicity Prediction. *Journal of Pharmaceutical Sciences and Research*, 9(5), 680–684.
- Saha P, Banerjee AK, Tripathi PP, Srivastava AK, R. U. (2020). A Virus that has Gone Viral: Amino Acid Mutation in S protein of Indian Isolate of Coronavirus COVID-19 Might Impact Receptor Binding, and Thus, Infectivity. *Biosci Rep*, 40(BSR20201312). <https://doi.org/10.1042/bsr20201312>

- Sakoulas G. (2020). Remdesivir: A Promising Antiviral Against Coronaviruses. <https://www.jwatch.org/na50889/2020/03/03/remdesivir-promising-antiviral-againstcoronaviruses>
- Saleh W. (2015). Studi Hubungan Kuantitatif Struktur-Aktivitas Anti-Tuberkulosis Senyawa Amidase Etil P-metoksisinamat dengan Pendekatan Hansch dan Penambatan Molecular pada Enzim InhA. UIN Syarif Hidayatullah.
- Schneider G, and B. K. (2008). Molecular Design: Concepts and Applications. *WILEY-VCH*.
- Sulaiman MZ, Maulana S, dan M. A. (2020). Penambatan Molekuler dan Simulasi Dinamika Molekuler Senyawa dari Genus *Nigella* terhadap Penghambatan Aktivitas Enzim Protease HIV-1. *Jurnal Farmasi Galenika*, 6(1), 132–140. <https://doi.org/10.22487/j24428744.2020.v6.i1.14982>
- Susanti NM., Laksyani NP, Noviyanti NK, Arianti KM, dan D. I. (2019). Molecular Docking Terpinen-4-OL sebagai Antiinflamasi pada Aterosklerosis secara In Silico. *Jurnal Kimia*, 13(2), 221–228.
- Susilo, A., Rumende, C. M., Pitoyo, C. W., Santoso, W. D., Yulianti, M., Herikurniawan, H., Sinto, R., Singh, G., Nainggolan, L., Nelwan, E. J., Chen, L. K., Widhani, A., Wijaya, E., Wicaksana, B., Maksum, M., Annisa, F., Jasirwan, C. O. M., & Yuniastuti, E. (2020). Coronavirus Disease 2019: Tinjauan Literatur Terkini. *Jurnal Penyakit Dalam Indonesia*, 7(1), 45. <https://doi.org/10.7454/jpdi.v7i1.415>
- Tambunan USF, Harganingtyas R, & P. A. (2012). In silico modification of (1R, 2R, 3R, 5S)-(-)- Isopinocampheylamine as inhibitors of M2 Proton Channel in Influenza A Virus Subtype H1N1, using the Molecular Docking Approach. *Trends in Bioinformatics*, 5(2), 25–46. <https://doi.org/10.3923/tb.2012.25.46>
- Wang Z, Qiang W, K. H. (2020). A Handbook of 2019-nCoV Pneumonia Control and Prevention. *Hubei Sci Technol Press*, 1–108.
- Wikipedia. (2021). *Molecular Dynamics*. https://en.m.wikipedia.org/wiki/Molecular_dynamics
- Williamson BN, Feldmann F, Schwarz B, Meade-White K, Porter DP, Schulz J, van Doremalen N, Leighton I, Yinda CK, Pérez-Pérez L, Okumura A, Lovaglio J, Hanley PW, Saturday G, Bosio CM, Anzick S, Barbican K, Cihlar T, Martens C, ... de Wit E Williamson BN, Feld, ... de Wit E. (2020). Clinical Benefit of Remdesivir in Rhesus Macaques Infected with SARS-CoV-2. *Nature*, 585(7824), 273–276. <https://doi.org/10.1038/s41586-020-2423-5>
- World Health Organization. (2021). *WHO Coronavirus (COVID-19) Disease Dashboard*.
- Wu Z, M. J. (2020). Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases from the Chinese Center for Disease Control and Prevention. *JAMA*.

- Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S, Qi F, Bao L, Du L, Liu S, Qin C, Sun F, Shi Z, Zhu Y, Jiang S, L. L. (2020). Inhibition of SARS-CoV-2 (Previously 2019-nCoV) Infection by a Highly Potent Pan-coronavirus Fusion Inhibitor Targeting its Spike Protein that Harbors a High Capacity to Mediate Membrane Fusion. *Cell Res*, 30, 343–355. <https://doi.org/10.1038/s41422-020-0305-x>
- Zhang W, Zhao Y, Zhang F, Wang Q, Li,T, Liu Z, ... & Zeng X. (2020). The use of Anti-inflammatory Drugs in the Treatment of People with Severe Coronavirus Disease 2019 (COVID-19): The experience of clinical immunologists from China. *Clinical Immunology*, 108393.
- Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. (2020). A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J Med*, 382(8), 727–733.
- Zumla A, Chan JFW, Azhar EI, Hui DSC, & Y. K. (2016). Coronaviruses - Drug Discovery and Therapeutic Options in Nature Reviews Drug Discovery. *Nature Publishing Group*, 15(5), 327–347. <https://doi.org/10.1038/nrd.2015.37>